All News
Matters of the heart: cardiovascular disease and mortality in RA
Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).
Read Article
EULAR 2024 – Day 2 Report (A Difficult RA Day)
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Read Article
Inflammatory bowel disease in spondyloarthritis - does it matter?
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
The fracture risk with glucocorticoids is dose dependent. Lems W #EULAR2024 @RheumNow https://t.co/TGjKu1vfXx
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with
efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
PsA: one composite index that does it all
cDAPSA + Investigator’s Global Assessment (IGA) of PSO
Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA
88% sensitivity & specificity in DISCOVER-1 & 2 trial data
#EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC
Aurelie Najm AurelieRheumo ( View Tweet)
🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer
38 PSO patients w/ arthralgia
Correlation PET/CT SUVmax, TJC & tender enthesis count
68Ga-FAPI-04 uptake = higher risk developing PsA 6mo
Shows signs of inflammation before MSUS!
#EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn
Aurelie Najm AurelieRheumo ( View Tweet)
Leflunomide for #PMR?
✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica
V fast withdrawal of #prednisone
#LEF ~4 to 5 months
#MTX 30 mos!
⬇️flares w LEF
😮
#EULAR2024 @RheumNow @eular_org
@SebaUltraTrail https://t.co/2hk0yMH6gY
Links:
Janet Pope Janetbirdope ( View Tweet)
Some of these drugs dont seem to work in all of knee OA. I guess its really difficult to tease out different subtypes.
Subgroup analysis from a Phase 3 intraarticular JTA-004 injection at #EULAR2024 abst#Op0305 @RheumNow https://t.co/jbkLYyl93e
Links:
Bella Mehta bella_mehta ( View Tweet)
🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry
➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs
➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Check point inhibitors may cause bone loss and fractures. Lems W #EULAR2024 @RheumNow https://t.co/rf1AU60Eah
Dr. Antoni Chan synovialjoints ( View Tweet)
This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Does TCZ switch off GCA histopathologically?
GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat)
Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary
#EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
Links:
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
Dr. John Cush RheumNow ( View Tweet)
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Dr. John Cush RheumNow ( View Tweet)
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope Janetbirdope ( View Tweet)
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN
PA Juge Juge_P_A ( View Tweet)
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Dr. John Cush RheumNow ( View Tweet)